Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

Exclusion Criteria

• •Have a diagnosis of any of the other forms of classic CAH.
• •Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy.
• •Have a clinically significant unstable medical condition or chronic disease other than CAH.
• •Have a history of cancer unless considered to be cured.
• •Have a known history of clinically significant arrhythmia or abnormalities on electrocardiogram (ECG).
• •Have a known hypersensitivity to any corticotropin-releasing hormone antagonist.
• •Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study.
• •Have current substance dependence or substance (drug) or alcohol abuse.
• •Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study.